Home » FDA Accepts Review of Long-Delayed Merck Blood Clot Drug
FDA Accepts Review of Long-Delayed Merck Blood Clot Drug
The FDA has accepted Merck’s marketing application for vorapaxar, an experimental drug that purports to treat patients with prior heart attacks, but without a history of strokes.
Reuters
Reuters
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May